BeOne Medicines Ltd.ONC

時価総額

$4435.2億

PER

がん治療の大手。CDACやバイスペシフィック、ADCなど多様な創薬プラットフォームとBRUKINSA・TEVIMBRAを展開。2019年10月のアムジェン提携と15億ドルの協業収入。世界6大陸に約3,700人の臨床チームと1,100人超の研究者で展開。

概要財務

サマリーテーブルに戻る

	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-119	-93	-674	-949	-1,597	-1,413	-2,004	-882	-645
Depreciation and amortization expense	-	5	10	19	32	46	66	88	172
Share-based compensation expense	11	43	87	134	183	241	303	368	442
Acquired in-process research and development	-	-	-	69	-	-	-	47	60
Amortization of Research And Development Financing Liability	-	-	-	-	-114	-112	-96	-55	-73
Unrealized losses on long-term investments	-	-	-	-	-	-	-	-	-24
Deferred income tax expense	-1	-6	-22	-9	-28	-41	2	1	26
Gain on BMS termination settlement	-	-	-	-	-	-	-	363	-
Other items, net	-	-	-	-9	7	24	9	-6	11
Accounts receivable	-	29	12	30	-10	423	-304	188	329
Inventories	-	11	5	12	59	153	57	141	91
Other assets	-	-	-	-	-	107	3	-12	-45
Accounts payable	3	55	23	2	96	20	-4	21	121
Accrued expenses and other payables	14	25	51	64	183	140	46	180	111
Deferred revenue	-	-	-	-28	-	408	-152	-256	1
Other liabilities	-	-	-	-	-	-	-1	1	-15
Net cash used in operating activities	-	13	-548	-750	-1,283	-1,299	-1,497	-1,157	-141
Purchases of property and equipment	24	46	70	90	118	263	325	562	493
Proceeds from sale or maturity of short-term investments	184	424	2,177	1,882	2,751	3,147	1,564	673	3
Purchase of in-process research and development	-	-	-	69	110	9	144	15	32
Purchase of intangible assets	-	-	1	-	-	43	-	19	5
Purchase of long-term investments	-	-	-	-	-	44	16	15	19
Other investing activities	-	-	-	-	-	-	-	-	3
Net cash (used in) provided by investing activities	-	-356	-638	554	-3,168	641	1,077	60	-548
Proceeds from long-term loan	-	-	42	67	-	17	37	23	9
Repayment of long-term loan	-	-	9	33	-	-	-	14	28
Proceeds from Short-Term Debt	-	2	-	-	-	406	314	662	868
Repayment of short-term loans	-	2	-	-	-	322	417	310	704
Proceeds from option exercises and employee share purchase plan	-	-	-	-	93	93	47	56	45
Other financing activities	-	-	-	-	-	-	-	-	3
Net cash provided by (used in) financing activities	-	490	1,691	86	5,203	3,637	-19	416	193
Effect of foreign exchange rate changes, net	-	-	-	-	18	14	-69	-8	-52
Net decrease in cash, cash equivalents, and restricted cash	-	-	501	-120	769	2,993	-508	-689	-547
Income taxes paid	-	29	12	9	11	16	30	56	69
Interest paid	-	-	-	-	-	-	-	-	51
Accruals for capital expenditures	2	2	22	29	43	53	95	92	70
Acquired In Process Research And Development But Not Yet Paid	-	-	-	-	-	75	-	32	60